We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Galera Therapeutics Inc (GRTX) USD0.001

Sell:$0.15 Buy:$0.16 Change: $0.0305 (16.58%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$0.15
Buy:$0.16
Change: $0.0305 (16.58%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$0.15
Buy:$0.16
Change: $0.0305 (16.58%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. It has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Contact details

Address:
45 Liberty Blvd., Suite 230
MALVERN
19355
United States
Telephone:
+1 (610) 7251500
Website:
https://www.galeratx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GRTX
ISIN:
US36338D1081
Market cap:
$10.01 million
Shares in issue:
54.39 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • J. Mel Sorensen
    President, Chief Executive Officer, Director
  • Christopher Degnan
    Chief Financial Officer, Secretary
  • Robert Beardsley
    Chief Operating Officer
  • Jennifer Stacey
    Chief Legal & Compliance Officer and Secretary
  • Eugene Kennedy
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.